OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 29, 2021
Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
November 01, 2020
Complex manufacturing processes pose challenges for final product inspection needed to ensure product integrity at commercial launch.
October 16, 2020
Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
October 01, 2020
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.
September 18, 2020
The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.
The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.
The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.